Later-line treatment with lorlatinib in ALK-and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis
Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Setinek, U; Krenbek, D; Prosch, H; Rauter, M; Schumacher, M; Woll, E; Wass, R; Brehm, E; Absenger, G; Bundalo, T; Errhalt, P; Urban, M; Valipour, A
WIEN KLIN WOCHENSCHR. 2020; 132(19-20): 610-610.
Abstracts (Zeitschrift)